SwitzerlandSwitzerland

Molecular Partners signs US$420 million contract on antibody mimetic with Allergan

05.05.2011

Zurich/Schlieren – Swiss Molecular Partners AG has bagged a US$45 million upfront payment and the option for additional US$345 million milestones from Allergan Inc for an exclusive licence of its Phase 2 anti-VEGF antibody mimetic MP0112 for the treatment of retinal diseases. In addition, Molecular Partners could receive tiered double-digit royalties on any future sales of MP0112. Allergan gains exclusive global rights for MP0112 for ophthalmic indications of the so-called DARPin molecule. DARPins are temperature stable, 14KDa scaffolds of 2-4 domains of the ankyrin protein motif that mimic the antigen binding capacities of antibody drugs while offering advantages of smaller molecules. Data on MP0112 from two separate phase I/IIa trials in wet age-related macular degeneration (wetAMD) and diabetic macular edema (DME) suggest that MP0112 is well-tolerated and has a potentially long lasting effect on vision gain after one single injection. In the studies, for most patients in the cohorts treated with the higher dose of the investigational compound, the potential beneficial effect on visual acuity lasted for approximately 16 weeks.

SwitzerlandSwitzerland

10.06.2011

Zurich – Overexpression of two microRNAs trigger development of insulin resistance, a hallmark of type II diabetes which affects about 20% of the elderly (aged 55-74) in the western world. In Nature, a research team headed by...

SwitzerlandSwitzerland

03.06.2011

Basel/Würzburg – Scientists from Swiss Novartis AG have cracked the mechanism that leads to permanent activation of the immune system in course of atherosclerosis and have targeted an antibody against it in mice and humans (JCI,...

SwitzerlandSwitzerland

27.05.2011

Basel - Scientists at Roche Holding AG's subsidiary Genentech have found a way to get antibodies across the blood-brain barrier that block the enzyme beta-secretase 1 which is believed to prevent formation of Alzheimer's plaques....

SwitzerlandSwitzerland

24.05.2011

Allschwil – Swiss biotech firm Actelion Pharma has reached the primary endpoint of preventing allergic rhinitis symptoms in patients challenged with Mountain Cedar pollen in a proof-of-concept study with its oral CRTH2...

SwitzerlandSwitzerland

13.05.2011

Basel – Swiss drugmaker Roche has filed for MAA in Europe and the U.S. for vemurafenib (RG7204, PLX4032 , RO5185426) in patients with malignant melanoma who carry the common B-Raf V600E mutation. The oral B-RAF blocker interrupts...

SwitzerlandSwitzerland

20.04.2011

Basel – Novartis COPD drug NVA237 (glycopyrronium bromide) has met the primary endpoint of superior bronchodilation to placebo at 12 weeks in a Phase III study with 800 participants, according to the Swiss drug giant’s...

SwitzerlandSwitzerland

15.04.2011

Zurich – Researchers under Prof Dario Neri from ETH Zurich have presented a new approach that cured squamous cell carcinoma in two mouse models (Br. J Cancer, doi: 10.1038/bjc.12.04.11). The founder of the biotech firm Philogen,...

SwitzerlandSwitzerland

12.04.2011

Zurich – Swiss Novartis AG has discontinued a Phase III head-to-head comparison of Tasigna (nilotinib) with the company’s US-$4 million blockbuster Glivec (imatinib) as first-line treatment of gastrointestinal stromal tumours...

Displaying results 41 to 50 out of 276

< Previous 41-50 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-switzerland/browse/4/article/molecular-partners-signs-us420-million-contract-on-antibody-mimetic-with-allergan.html

Stock list

All quotes

TOP

  • MAGFORCE (D)5.90 EUR9.26%
  • ABCAM (UK)387.00 GBP7.72%
  • NANOBIOTIX (F)17.40 EUR7.27%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • NOVACYT (F)4.40 EUR-8.33%

TOP

  • WILEX (D)3.12 EUR310.5%
  • SANTHERA (CH)69.30 CHF132.6%
  • ADDEX (CH)4.07 CHF89.3%

FLOP

  • MERCK KGAA (D)63.71 EUR-50.0%
  • THROMBOGENICS (B)8.87 EUR-38.3%
  • HYBRIGENICS (F)1.72 EUR-34.1%

TOP

  • SANTHERA (CH)69.30 CHF3365.0%
  • GW PHARMACEUTICALS (UK)438.00 GBP812.5%
  • PAION (D)2.80 EUR311.8%

FLOP

  • CYTOS (CH)0.25 CHF-92.7%
  • EVOCUTIS (UK)0.21 GBP-92.1%
  • THROMBOGENICS (B)8.87 EUR-71.1%

No liability assumed, Date: 22.07.2014


Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events